Precigen Inc (PGEN)
Healthcare
Biotechnology
6.50 $
-1.2%
vs. previous close
Closing price · As of: 4. Aug 2026
All figures as a percentage of revenue in the same period.
| Tick rows to compare them in a chart (up to 4) | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 96.0% | 111.5% | 209.0% | 176.1% | 141.4% | 105.9% | 98.2% | 105.8% | 181.7% | 46.3% | 41.9% | 12.4% | 24.4% | |
| 4.0% | -11.5% | -109.0% | -76.1% | -41.4% | -5.9% | 1.8% | -5.8% | -81.7% | 53.7% | 58.1% | 87.6% | 75.6% | |
| 672.0% | 840.0% | 1,058.1% | 1,337.9% | 2,188.7% | 1,193.1% | 988.1% | 757.6% | 1,342.1% | 412.7% | 146.2% | 22.9% | 112.5% | |
| 527.2% | 666.9% | 835.9% | 953.1% | 1,437.4% | 1,032.1% | 924.4% | 921.6% | 1,884.7% | 821.0% | 386.5% | 90.5% | 249.5% | |
| 1,199.2% | 1,506.8% | 1,795.6% | 2,216.2% | 8,444.1% | 2,225.2% | 2,398.1% | 1,679.2% | 3,629.1% | 1,233.7% | 532.7% | 113.4% | 372.8% | |
| -1,195.2% | -1,518.3% | -1,904.6% | -2,292.3% | -8,485.5% | -2,231.1% | -2,396.3% | -1,685.0% | -3,710.7% | -1,180.0% | -474.6% | -25.8% | -297.2% | |
| 7.7% | 0.1% | 0.6% | 0.2% | 0.3% | 0.2% | 0.5% | 0.1% | 0.0% | 30.9% | 64.9% | 12.5% | 21.4% | |
| -1,153.6% | -1,435.9% | -2,718.9% | -2,231.6% | -8,435.3% | -2,514.8% | -1,665.0% | -4,038.3% | -3,112.0% | -5,008.4% | -514.9% | -34.1% | -647.0% | |
| -3.7% | -0.4% | -27.0% | -2.7% | -235.6% | 1.3% | -7.3% | -6.5% | 0.4% | 6,125.9% | 0.1% | – | – | |
| -1,149.9% | -1,435.5% | -2,691.9% | -2,228.9% | -8,199.7% | -2,516.1% | -1,657.7% | -4,038.3% | -3,112.4% | -5,008.4% | -514.9% | -34.1% | -647.0% | |
| -1,050.1% | -1,316.2% | -2,586.9% | -2,081.7% | -8,212.4% | -2,443.9% | -1,609.5% | -3,991.3% | -3,180.7% | -4,950.0% | -425.0% | -16.9% | -617.8% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: August 4, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.